Our evidence solutions include:
- HEOR, value and access (including pricing)
- Integrated evidence planning (IEP)
- Value proposition/value story/evidence gap analysis
- HEOR/HTA advisory boards
- Appraisal review/HTA/scientific advice
- Outcomes-based contracting
- Competitive landscape
- Pricing and reimbursement landscape assessment
- Analog assessment
- PRO landscape
- Policy landscape
- Rapid evidence synthesis/Disease state profiling
- Disease model
- Economic model (BIM, CEM, Breakeven model)
- Cost calculator
- Global patient funnel
- Model adaptations
- Meta analysis and indirect comparisons
- Preference survey
- Value dossiers (GVD, AMCP)
- Tool and resources for customer-facing teams (MSL, HOLs, AM)
- Response letter and submissions to HTAs
- Objection handlers
- Access playbook
- Integrated Evidence Generation Planning playbook
“We are impressed with the efficiency and quality of the work, your leadership skills, and the extra efforts you've made to ensure the results are absolutely accurate."
- General medicine
- Infectious diseases
- Mental health
- Nephrology/ Renal disease
- Obstetrics/ Gynecology
- Pulmonology/ Respiratory
Accelerated Insight Generation
Where agile technology meets HEOR expertise
Our expert HEOR teams leverage a suite of technology platforms to optimize evidence generation and communication.
EVID AI enhances and accelerates literature reviews; RPR secures robust stakeholder insights at any stage of the process; and our interactive RWE Dashboards transform complex data into digestible insights.
Additionally, we have developed Integrated Evidence Planning platforms to meet the challenge of evidence organization and communication, providing optimal visibility to internal stakeholders and ensuring proper alignment across functional and geographic teams.
Rapid stakeholder insights
HEOR Case Study
Focal segmental glomerulosclerosis: evaluate HCRU and burden of illness
Focal segmental glomerulosclerosis (FSGS) is a varied, complex pattern of kidney damage that has several different causes and numerous names and terminology, as well as different proposed classification systems.
Evidence generation required (1.) claims to summarize the cost and HCRU burden and (2.) clinical data (e.g. labs from EHR) to accurately identify patients in the study cohort.
We collaborated with the client to develop a protocol and analysis plan.